IMMXImmix Biopharma, Inc.

Healthcare
$9.30+271% 1Y

The financials

Immix Biopharma, Inc. by the numbers

Immix Biopharma, Inc. income statement, Q2 2026 against the same quarter a year earlier
Income statementQ2 2026Q2 2025Change
Operating income−$12M−$6.7Mn/a
Net income−$12M−$6.6Mn/a
Diluted EPS−$0.18−$0.22n/a

Biotechnology

Ranks #162 of 196 by RyuScore

Compare peers
FDMT+0.79%
4D Molecular Therapeutics, Inc.
GUTS-7.4%
FRACTYL HEALTH, INC.
GYRE-3.8%
GYRE THERAPEUTICS, INC.
SLDB-0.51%
Solid Biosciences Inc.
ANNX-0.99%
Annexon, Inc.
AURA+0.62%
Aura Biosciences, Inc.